| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697551 | Cancer Treatment Reviews | 2017 | 29 Pages |
Abstract
UM is little responsive to ipilimumab regardless of dosage schemes. Sound randomized clinical trials are needed to evaluate the efficacy of combined ICB in patients with UM.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Markus V. Heppt, Theresa Steeb, Justin Gabriel Schlager, Stefanie Rosumeck, Corinna Dressler, Thomas Ruzicka, Alexander Nast, Carola Berking,